Jove
Visualize
Contact Us
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Identification Of C-plan Index As A Novel Prognostic Predictor For Advanced Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors

Jiaxin Wang1, Huaijuan Guo1, Jingjing Yang1

  • 1Department of Oncology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.

Frontiers in Oncology
|February 23, 2024

Related Experiment Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

View abstract on PubMed

Summary
This summary is machine-generated.

A new C-PLAN index, combining C-reactive protein (CRP), Performance Status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR), effectively predicts outcomes for advanced lung cancer patients on immune checkpoint inhibitor (ICI) therapy.

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Immunotherapy

Background:

  • Non-invasive prognostic biomarkers are crucial for advanced lung cancer patients undergoing immune checkpoint inhibitor (ICI) therapy.
  • Existing biomarkers may not fully capture the complex prognostic landscape.

Purpose of the Study:

  • To develop and validate a novel, integrated prognostic predictor for patients with advanced lung cancer receiving ICI-based therapy.
  • To assess the predictive capability of the C-PLAN index for progression-free survival (PFS) and overall survival (OS).

Main Methods:

  • Retrospective analysis of 192 advanced lung cancer patients treated with ICI.
  • Development of the C-PLAN index by integrating pretreatment levels of C-reactive protein (CRP), Performance Status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR).
Keywords:
C-PLANbiomarkerimmune checkpoint inhibitorlung cancer

Related Experiment Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  • Kaplan-Meier analysis and multivariate Cox regression to evaluate the prognostic significance of the C-PLAN index.

    • Main Results:

    • A high C-PLAN index was significantly associated with worse PFS and OS (p<0.001) in ICI-treated lung cancer patients.
    • Multivariate analysis confirmed high C-PLAN index as an independent unfavorable prognostic factor for PFS (HR=1.821) and OS (HR=2.058).
    • A nomogram incorporating C-PLAN index, age, gender, TNM stage, and smoking status demonstrated good predictive accuracy for 1-, 2-, and 3-year survival.

    Conclusions:

    • The C-PLAN index serves as a valuable, non-invasive, and cost-effective prognostic tool for advanced lung cancer patients receiving ICI therapy.
    • The C-PLAN index can aid in risk stratification and personalized treatment strategies for lung cancer patients.
    • Further validation in prospective studies is warranted to confirm the clinical utility of the C-PLAN index.
    prognosis